Cyclacel Pharmaceuticals/ US23254L8019 /
2024-10-18 9:59:58 PM | Chg. +0.08 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
1.13USD | +7.62% | 22,946 Turnover: 33,001.04 |
-Bid Size: - | -Ask Size: - | 1.94 | 1.07 |
GlobeNewswire
08-14
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
GlobeNewswire
06-26
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceuti...
GlobeNewswire
06-04
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024...
GlobeNewswire
06-03
Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fad...
GlobeNewswire
05-14
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
GlobeNewswire
05-02
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Un...
GlobeNewswire
04-30
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq ...
GlobeNewswire
04-01
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadra...
GlobeNewswire
03-19
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Bu...
GlobeNewswire
03-13
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire
03-07
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented...
GlobeNewswire
01-30
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
GlobeNewswire
01-08
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
GlobeNewswire
2023-12-22
Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Ma...
GlobeNewswire
2023-12-18
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CD...
GlobeNewswire
2023-11-30
Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
GlobeNewswire
2023-11-28
Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Repor...
GlobeNewswire
2023-11-13
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update